F43. POTENTIATION OF INHIBITORY NEUROTRANSMISSION IN THE TREATMENT OF RECENT-ONSET SCHIZOPHRENIA BY MODIFICATION OF DEVELOPMENTAL PRUNING OF PREFRONTAL CIRCUITRY by Burke, Erin et al.
F43. POTENTIATION OF INHIBITORY
NEUROTRANSMISSION IN THE TREATMENT
OF RECENT-ONSET SCHIZOPHRENIA
BY MODIFICATION OF DEVELOPMENTAL
PRUNING OF PREFRONTAL CIRCUITRY
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Burke, Erin, Joanne Wojcik, Larry J Seidman, Alan Green, and
Tsung-Ung Wilson Woo. 2018. “F43. POTENTIATION OF INHIBITORY
NEUROTRANSMISSION IN THE TREATMENT OF RECENT-ONSET
SCHIZOPHRENIA BY MODIFICATION OF DEVELOPMENTAL
PRUNING OF PREFRONTAL CIRCUITRY.” Schizophrenia Bulletin
44 (Suppl 1): S235-S236. doi:10.1093/schbul/sby017.574. http://
dx.doi.org/10.1093/schbul/sby017.574.
Published Version doi:10.1093/schbul/sby017.574
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37067603
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Abstracts for the Sixth Biennial SIRS Conference
Poster Session II  S235
1Lancaster University; 2University of Strathclyde; 3University of 
Strathclyde, Strathclyde Institute Pharmacy & Biomedical Science; 
4University of Glasgow 
Background: Duplication at 16p11.2, affecting approximately 30 genes, 
has consistently been associated with increased risk of schizophrenia 
(Psychiatric Genomics Consortium, 2017. Nat Genet 49: 27). We currently 
have little understanding of how this CNV impacts on brain and neuro-
transmitter system function. Here we use a mouse model of 16p11.2 dupli-
cation (7DUP mice, Horev et  al. 2011. PNAS. 108: 17076)  to determine 
the impact of this CNV on cerebral metabolism. In addition, we charac-
terize in vivo glutamate and monoamine neurotransmitter system function 
by challenging these animals acutely with ketamine and d-amphetamine, 
respectively.
Methods: 7DUP mice and littermate controls were treated with ketamine 
(25mg/kg), d-amphetamine (5mg/kg), or saline (2ml/kg). n=11 (6 male, 5 
female) for each genotype per treatment group. Cerebral metabolism was 
determined by 14C-2-deoxyglucose functional brain imaging (Dawson 
et al., 2015.Transl Psychiatry. 5:e569). Data were analysed using repeated 
measures ANOVA with post-hoc Tukey’s HSD.
Results: 7DUP mice show significant constitutive hypometabolism in the 
thalamic reticular nucleus, mesolimbic system, and in neuromodulatory 
brain regions. Hypometabolism was also seen in the striatum of female, but 
not in male, 7DUP mice. 7DUP mice were also found to show hyperme-
tabolism in the hippocampus, amygdala, and cerebral cortex. The impact 
of ketamine on cerebral metabolism is attenuated in 7DUP mice with sex 
specific effects, being evident in the mesolimbic and neuromodulatory sys-
tem of males, whereas the attenuation is present in the hippocampus and 
striatum in female mice. By contrast, 7DUP mice showed an exaggerated 
response to d-amphetamine. Again, these effects were influenced by sex, 
with the exaggerated response being significantly more widespread in males 
than in females.
Discussion: 7DUP mice show altered constitutive cerebral metabolism in 
brain regions implicated in schizophrenia, including hippocampal and 
temporal cortex hyperactivity. In addition, 7DUP mice demonstrate a 
reduced response to ketamine, supporting NMDA receptor hypofunc-
tion as a result of  16p11.2 duplication. This effect is consistent with 
the glutamate hypofunction hypothesis of  schizophrenia. By contrast, 
7DUP mice show an exaggerated response to d-amphetamine, support-
ing monoamine neurotransmitter system dysfunction as a consequence 
of  16p11.2 duplication. Intriguingly, each of  these effects differs in male 
and female mice, suggesting that the phenotypic impact of  16p11.2 
duplication is influenced by sex. These data provide new insight into 
the mechanisms through with 16p11.2 duplication increases the risk of 
developing schizophrenia.
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Background: Emerging evidence from our group and others has brought the 
brain extracellular matrix (ECM) to the forefront of investigations on brain 
disorders. Our group has shown that organized perisynaptic ECM aggre-
gates, i.e. perineuronal nets (PNNs) are decreased in several brain regions 
in people with schizophrenia (SZ) and bipolar disorder (BD). PNNs were 
detected by their expression of specific chondroitin sulfate proteoglycans 
(CSPGs), main components of the ECM, thought to play a key role in syn-
aptic regulation during development and adulthood. Our studies have also 
shown that glial cells expressing CSPGs are altered in these disorders, sug-
gesting a link between glial cell and PNN abnormalities. Finally, we have 
recently shown that novel CSPG structures, bearing a distinct CS-6 sulfa-
tion pattern and named CS-6 glial clusters, are decreased in the amygdala 
of people with SZ and BD. The morphology and function of CS-6 glial 
clusters is not currently known, but evidence from rodents and on the role 
of CSPGs in regulating synaptic functions strongly suggest that they may 
affect synaptic plasticity. We tested this hypothesis using a combination of 
human postmortem and rodent brain studies.
Methods: High Resolution electron microscopy was used to investigate the 
ultrastructural organization of CS-6 glia clusters. A transgenic mouse model 
expressing green fluorescent protein in a subset of excitatory pyramidal neu-
rons was used to investigate dendritic spines association with CS-6 glia clus-
ters. Mice were exposed to a single session of auditory fear conditioning for 
a total of 15 minutes. Animals were euthanized 4 hours after behavioral test. 
Multiplex immunocytochemistry was used to visualize CS-6 clusters.
Results: In human tissue, we show that CS-6 glia clusters are widespread 
in several brain regions, including the amygdala, entorhinal cortex, thal-
amus and hippocampus. Ultrastructural results show that CS-6 glia clus-
ters are formed by CS-6 accumulations surrounding several dendrites. 
CS-6 expression was dected in astrocytes surrounding the dendrites, 
particularly in astrocytic endfeet enveloping dendritic spines, and within 
spines postsynaptic densities. Following auditory fear conditioning, 
marked changes of  CS-6 glia clusters were observed in hippocampus 
regions dentate gyrus (g>1.5) and CA2 (g>1.5) and basolateral amyg-
dala (g>1).
Discussion: These findings suggest that CS-6 glia clusters may repre-
sent segregated microdomains, dynamically regulated during learning 
and contributing to the modulation of  synaptic regulation machinery. 
Specifically, we postulate that astrocytes synthesize CS-6 CSPG and 
secrete it through their endfeet around dendrites, modulating structural 
plasticity of  dendritic spines. These results suggest a relationship between 
the abnormalities in CSPGs expression and alteration in dendritic spines, 
two pathological landmarks observed in postmortem brains of  people 
with SZ and BD.
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Background: The overt symptoms and deficits of schizophrenia (SZ) typ-
ically emerge during late adolescence and early adulthood, followed by a 
period of post-onset functional deterioration. This peri-onset period tem-
porally coincides with the final maturation of the prefrontal cortex (PFC), 
which is characterized by a process of extensive pruning of synaptic con-
nectivities. Developmental maturation of inhibitory neurotransmission 
may play a key role in regulating the onset and duration of peri-adoles-
cent synaptic pruning. We hypothesize that a deficit in the developmen-
tal increase in inhibitory neurotransmission may disturb the PFC synaptic 
pruning process and hence contribute to the onset and the functional dete-
rioration that is characteristic of the early course of SZ. Enhancement of 
inhibitory neurotransmission may therefore restore the integrity of PFC 
neural circuitry, which may then lead to lasting improvements in cognitive 
deficits and clinical symptoms.
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Methods: Here, we report preliminary data on the possible efficacy of 
tiagabine (Gabitril), which is a selective uptake inhibitor of the GABA 
(gamma-aminobutyric acid) transporter GAT-1, in the treatment of recent-
onset schizophrenia. Subjects were randomized to receive either tiagabine 
or placebo added on to their antipsychotic regimen.
Results: Our data suggest that treatment with tiagabine during the early 
course of the illness can modulate PFC activation, as demonstrated by 
functional magnetic resonance imaging during working memory, and 
improve negative symptoms.
Discussion: Taken together, the proposed treatment strategy represents an 
effort to actively translate preclinical findings in SZ research into clinically 
testable hypotheses. This kind of translational approach, we believe, will ulti-
mately lead to breakthrough in the treatment and possible prevention of SZ.
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Background: Oxidative stress, coupled with dysregulation of inflammation, 
NMDAR and dopamine, is involved in schizophrenia (SZ) pathophysiology. 
Earlier add-on clinical trials showed in chronic SZ patients that NAC, a pre-
cursor of glutathione (GSH), an important cerebral antioxidant, improved 
negative symptoms, mismatch negativity and local synchronization. We hypoth-
esized that NAC at an earlier stage of illness would have a greater impact.
Methods: Early psychosis patients (EP, less than 5 years of illness, N=63; 
NAC=32, placebo=31) were supplemented with NAC (2.7g/day, 6 months) 
in a double-blind randomized placebo-controlled trial. Outcome measures: 
PANSS and neurocognition (MATRICS Consensus Cognitive Battery; 
n=36); quantification of medial prefronfal cortex glutathione (GSHmPFC) 
by 1H-magnetic-resonance-spectroscopy, of white matter diffusion proper-
ties estimated by generalized fractional anisotropy (gFA) computed from 
diffusion spectrum imaging (DSI), of blood cells GSH (GSHBC) and GSH 
peroxidase activity (GPxBC) at start and end of trial
Results: While PANSS negative and positive were not affected by NAC, 
NAC improved Processing Speed (NAC > Placebo; F(1, 30)=5.849, 
p=.022), favoring 2 of 3 processing speed tasks (Trail Making A, 
F(1, 30)=4.279, p=.048  & Verbal Fluency, F(1, 30)=5.749, p=.023). 
GSHmPFC (+23%, p=0.005) and GSHBC (+19%, p=0.05) were increased 
following NAC treatment. In patients with high-baseline GPxBC (>22.3U/
gHb), subgroup explorations revealed an improvement of PANSS positive 
compared to placebo (p=0.02). The change of PANSS positive correlated 
negatively with that of GPxBC activity, showing that the improvement par-
alleled the restoration of redox status. NAC group showed 11% increase 
in fornix white matter integrity as measured by gFA, correlating with an 
increase in GSHmPFC over the 6-months period.
Discussion: This is the first clinical trial assessing the impact of NAC treatment 
in a sample of EP and the potential predictive role of peripheral biomarkers of 
redox dysregulation. The hypothesis that NAC would be beneficial to negative 
symptoms in EP was not confirmed in this small sample, most likely in rea-
son of their very low level at baseline. The NAC induced GSHmPFC increase 
demonstrates its target engagement. NAC improved Processing Speed show-
ing a therapeutic enhancement of cognitive functions. Most importantly, NAC 
improved fornix integrity, in association with brain GSH elevation, demon-
strating for the first time that a redox regulator can enhance structural connec-
tivity. Peripheral redox status allows identifying a subgroup of patients with 
improved positive symptoms. Future biomarker guided antioxidant interven-
tions in larger EP samples should replicate these findings.
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Background: The aim of this study was to investigate the efficacy and safety 
of blonanserin treatment after switching from other atypical antipsychotics in 
schizophrenic inpatients who showed inadequate efficacy and poor tolerability.
Methods: A total of 63 schizophrenic inpatients (inadequate response group=45 
and poor tolerability group=18) were included in this study. They were already 
treated with atypical antipsychotics except blonanserin and not favored due to 
inadequate responses or intolerable adverse effects. Blonanserin was administered 
during 12 weeks after switching from their previous antispsychotics. Treatment 
response was evaluated with Brief Psychiatric Rating Scale (BPRS) and CGI-
S, and safety profile were measured with Abnormal Involuntary Movement 
Scale (AIMS), Simpson-Angus Extrapyramidal Side effects Scale (SAR)S and 
Barnes Akathisia Rating Scale (BARS). Drug Attitude Inventory (DAI-10) and 
Subjective Well-being Under Neuroleptic Treatment (SWN) were used for sub-
jective estimates. Assessments were done at baseline, 1, 2, 4, 8 and 12 weeks after 
blonanserin treatment. Repeated measures of ANOVA were done to analyze the 
group (inadequate vs. intolerable group) and time effects.
Results: CGI and BPRS were showed significant treatment responses after 
switching to Blonaserin. Time effects were significant at 2, 4, 8, 12 weeks 
after switching and group by time effect were also significant at that time. 
Mean changes of AIMS, SARS and BARS scores were not significant 
throughout test trial. Although SWN was significantly improved after 
switching to Blonaserin, it was not found significant group by time effect.
Discussion: The results suggest that blonanserin may be effective and well 
tolerable in schizophrenic patients who showed inadequate treatment 
response or poor tolerability.
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